Phase 2C clinical trial of novel short-course regimens for the treatment of pulmonary tuberculosis: TBTC study 38/CRUSH-TB design.

Journal:

Contemporary clinical trials, Volume: 158

Published:

November 5, 2025

PMID:

40915316

Authors:

Ekaterina V Kurbatova EV, Kelly E Dooley KE, Wendy Carr W, Jason E Stout JE, Eric L Nuermberger EL, Patrick P J Phillips PPJ, Nigel A Scott NA, Caryn M Upton CM, Elisa Ignatius E, Michelle Haas M, Nicholas D Walter ND, Rita M Traxler RM, Nicole E Brown NE, Rosanna Boyd R, Kia E Bryant KE, Meredith G Dixon MG, Rada Savic R, Christie Eichberg C, Anneke Hesseling A, Charles Bark C, Debra A Benator DA, Grace Muzanyi G, Nicholas S Twycross NS, Greg J Fox GJ, Samuel Pierre S, Joseph Burzynski J, Daniel W Fitzgerald DW,

Access Paper

DOI: 10.1016/j.cct.2025.108075

PMID: 40915316

Abstract:

Preclinical and clinical study data show that combining bedaquiline (B or BDQ), moxifloxacin (M), and pyrazinamide (Z), known as BMZ, has potent antimicrobial activity that might shorten treatment duration for drug-susceptible pulmonary tuberculosis.

Courtesy of the U.S. National Library of Medicine